share_log

CRISPR Therapeutics | 8-K: Current report

SEC announcement ·  Jan 16 13:00
Summary by Futu AI
CRISPR Therapeutics AG, a biotechnology company, announced that the U.S. Food and Drug Administration (FDA) has approved its gene-edited cell therapy, CASGEVY™ (exagamglogene autotemcel [exa-cel]), for the treatment of transfusion-dependent beta thalassemia in patients aged 12 years and older. The approval, dated January 16, 2024, marks a significant milestone for the company, which specializes in CRISPR/Cas9 gene-editing technology. The therapy represents a new option for patients suffering from this genetic blood disorder, which previously required regular blood transfusions. The announcement was made in a Form 8-K filing with the Securities and Exchange Commission by CRISPR Therapeutics AG.
CRISPR Therapeutics AG, a biotechnology company, announced that the U.S. Food and Drug Administration (FDA) has approved its gene-edited cell therapy, CASGEVY™ (exagamglogene autotemcel [exa-cel]), for the treatment of transfusion-dependent beta thalassemia in patients aged 12 years and older. The approval, dated January 16, 2024, marks a significant milestone for the company, which specializes in CRISPR/Cas9 gene-editing technology. The therapy represents a new option for patients suffering from this genetic blood disorder, which previously required regular blood transfusions. The announcement was made in a Form 8-K filing with the Securities and Exchange Commission by CRISPR Therapeutics AG.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.